114 results about "Anti platelet" patented technology

In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

The utility model discloses a cardiac muscle patch with a microneedle for cardiac bypass, which comprises a patch main body used for being adhered and wrapped on the surface of a vein bridge blood vessel in a cardiac bypass operation; the plurality of microneedles are uniformly distributed on the adhesive surface of the patch main body, and drug particles are attached to the surfaces of the microneedles; and the reinforced connection structures are uniformly distributed on the surface of the patch main body, are connected to the interiors of the microneedles, and are used for reinforcing the connection between the microneedles and the patch main body. According to the myocardial patch with the micro-needle for heart bypass, the surface of the patch is combined with the hydrogel micro-needle to form an integrated structure, so that loaded drugs, such as antiplatelet tirofiban sustained-release particles, are loaded to the needle body of the micro-needle, and continuous and stable release of the tirofiban sustained-release particles can be ensured; the myocardial patch is directionally conveyed to a vein bridge area, so that simple and convenient application of the myocardial patch in a vein bridge is facilitated.

The invention discloses an antibacterial and antithrombotic medical catheter and a preparation method thereof. According to the medical catheter, a hydrogel coating is prepared on the surface of the medical catheter, the hydrogel coating contains a three-layer structure, and the medical catheter has low swelling property and excellent mechanical property, stability, durability, platelet adhesion resistance, antibacterial property and biocompatibility. The preparation method disclosed by the invention is simple, efficient and environment-friendly; the dopamine layer provides strong adhesion performance, glucose oxidase entrapped in FDA provides longer-term antibacterial performance, and finally the carboxylic acid betaine zwitterionic coating is introduced to further enhance the antithrombotic performance of the hydrogel coating, so that the hydrogel coating medical catheter is produced. The invention provides a new strategy for the low-expansion amphiphilic ion hydrogel coating with antithrombotic and antibacterial properties in the field of biomedical materials, especially as a medical catheter, and the coating can be applied to biomedical equipment in contact with blood.

In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

The invention discloses an intracavity anchor, a preparation method thereof and a blood vessel occlusion device. Relates to the technical field of medical instruments, in particular to an intracavity anchor which comprises an anchor body and a medicine carrying coating, the surface of the anchor body is coated with the medicine carrying coating, and the medicine carrying coating comprises at least one of anti-platelet adhesion medicine, anti-coagulation medicine, anti-proliferation medicine and anti-infection medicine. The intracavitary anchor provided by the invention has excellent anticoagulation, anti-proliferation and anti-infection capabilities, can effectively reduce the generation of clinical complications, avoids the need of long-term medicine taking of patients, reduces the pain and risk of the patients during treatment, and further enables the vascular structure and function to recover to a healthy state as soon as possible.

The present invention relates to methods for determining a blood gas parameter and / or a basic metabolic panel parameter in a blood sample comprising combining the blood sample with an anti-coagulant and an anti-platelet agent, and determining said blood gas parameter and / or parameter in the sample. In some aspects, the invention relates to determining said parameters in samples that have been subjected to pre-analytical stress.

The invention discloses application of compound resina draconis in preparation of a medicine for treating acute myocardial infarction. The compound resina draconis has the effects of resisting free radical oxidation and platelet aggregation, expanding coronary artery, inhibiting increase of myocardial enzymology CPK and LDH and reducing myocardial oxygen consumption, so that the myocardial infarction range is reduced, and myocardial ischemic ST segment elevation is improved; the compound is combined with aspirin for treating acute myocardial infarction, and the compound and aspirin have a synergistic effect, play a role in resisting platelet aggregation and inhibit synthesis of thromboxane A2, and show a good ischemic myocardial protection effect. Meanwhile, according to the technical scheme that the compound resina draconis is used independently or combined with aspirin, the application range of the medicine is widened, contribution is made for research and development of the medicine for relieving side effects caused by aspirin treatment, and the application prospect is good.

Described herein are methods and kits for the detection of platelet-activating pathogenic antibodies in samples from patients suspected of having platelet-activating antibodies or non-HIT anti-PF4 antibody mediated syndromes using platelets and polyvinyl sulfonate or salts thereof. Upon platelet activation, thrombospondin-1 (TSP1), a platelet granule protein, is released and can be detected using a TSP1 antigen capture enzyme linked immunosorbent assay (ELISA) to accurately measure platelet activation.

The invention relates to an anti-thrombotic molecule having both antiplatelet and anticoagulant (APAC) activity; its use as a medicament; its selective configuration and use as an anticoagulant and platelet inhibitor, or its selective configuration and use predominantly as either an anticoagulant or a platelet inhibitor; and a method for its production.

Aminopyrimidine containing compounds that inhibit both Mer tyrosine kinase (MerTK) activity and Tyro3 kinase activity are disclosed herein. Additionally disclosed are methods of synthesis and use of the aminopyrimidine containing compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents.

This invention relates to the fields of molecular biology and biomedicine, disclosing plasma-active peptides with antithrombotic effects and their uses. The invention obtains various active peptides from plasma through screening and solid-phase synthesis, and confirms their biological activity through in vitro platelet aggregation experiments and in vivo arterial thrombosis model experiments. Results show that peptides 1957, 1960, and 1961 significantly inhibit collagen-induced platelet aggregation, exhibiting good antiplatelet activity; animal experiments show that peptides 1955, 1957, 1960, and 1961 significantly inhibit arterial thrombosis. These active peptides are derived from endogenous plasma components, belonging to natural antithrombotic substances, possessing good physiological compatibility and safety advantages, and reducing the risk of immunogenicity and adverse reactions. These peptides can exert antithrombotic effects without relying on traditional antiplatelet drugs, providing a new source of active molecules and treatment options for the prevention and treatment of thrombotic diseases.

The application belongs to the technical field of pharmaceutical preparations, and specifically provides a kind of indobufen freeze-dried oral disintegrating tablet and a preparation method thereof.The freeze-dried oral disintegrating tablet contains indobufen and xanthan gum, and the freeze-dried oral disintegrating tablet can be obtained by freeze-drying technology after the above components are prepared into a suspension.The freeze-dried oral disintegrating tablet provided by the application has the technical characteristics of good properties, complete demolding, high drug loading, good content uniformity, rapid disintegration and rapid dissolution, and can meet the needs of rapid anti-platelet therapy in acute thrombosis events.

The present application relates to the technical field of in vitro detection, and particularly relates to a platelet aggregation function detection reagent and application thereof.The platelet aggregation function detection reagent provided by the present application comprises a fibrin activator and an ADP reagent, the fibrin activator adopts a novel high-purity porcine dermal collagen polypeptide component Prionex, and the combination with glycine significantly improves the stability of the fibrin activator, the platelet inhibitor tirofiban is used in combination with PEG6000, the accuracy of the detection result is improved, and the sensitivity to the anti-platelet aggregation drug is improved; the ADP reagent adopts chitosan, the activity and stability are improved, and the ADP reagent can be widely applied to clinical diagnosis of platelet aggregation function.

The invention belongs to the technical field of medicines, and discloses application of pantethine in preparation of medicines for preventing and / or treating thrombotic diseases or medicines for inhibiting platelet activation or regulating vascular endothelial cell functions. In-vivo and in-vitro experiments prove that pantethine can remarkably relieve thrombus load in a mouse thrombus model, down-regulate expression of vWF (von Willebrand Factor), up-regulate expression of TFPI (Tissue Factor Path Inhibitor) and TH BD (Thromboregulatory Protein), and antagonize platelet adhesion, aggregation and activation induced by a platelet activator. The action mechanism is closely related to inhibition of reactive oxygen species (ROS) generation and NF-kappa B signal channel activation, and improvement of endothelial cell functions. It can be known from the invention that pantethine plays an antithrombotic role from multiple aspects, and is suitable for preparation of antithrombotic drugs for prevention or treatment. The invention provides a new drug choice for prevention and treatment of thrombotic diseases.

The application belongs to the technical field of biotechnology, and particularly relates to a kind of snake venom polypeptide and application thereof.The snake venom polypeptide is polypeptide DACU-1, polypeptide DACU-2 or polypeptide DACU-3.The application provides a kind of new snake venom polypeptide, including three polypeptides, and the three polypeptides all have anti-platelet aggregation activity, and have the activity of inhibiting platelet aggregation under the stimulation of ADP, arachidonic acid, collagen, thrombin and other various activators, and have the potential to be developed into anti-platelet drugs, functional foods and health products.

The application discloses a preparation method and application of a paeonol derivative, and relates to the technical field of biomedicine. The paeonol derivative has the chemical structure as shown in the following formula: or. The paeonol extraction preparation method is simple, and the extraction rate of the paeonol is high. The prepared paeonol derivative has more excellent antioxidant activity, and the anti-inflammatory effect is enhanced, the anti-platelet aggregation effect is better, and the paeonol derivative also has good inhibitory activity on the occurrence and development of diabetic retinopathy.

The invention relates to the technical field of medicinal chemistry, in particular to a novel carbamate fumarate, and a crystal form, an amorphous form and a preparation method thereof. The carbamate fumarate and the crystal form and the amorphous form thereof have high stability and solubility and low hygroscopicity, the medicinal performance is improved, the platelet aggregation resisting effect is better, the medicine effect is higher, and clinical application of the medicine is facilitated.

The invention relates to the technical field of medicines, in particular to application of benzbromarone in preparation of antithrombotic drugs. The research finds that benzbromarone clinically used for treating hyperuricemia can be combined with HSP47 on platelets to inhibit the interaction between the HSP47 and collagen so as to reduce platelet activation and thrombosis, which prompts that benzbromarone is an HSP47 inhibitor with an anti-platelet effect; benzbromarone has the effects of inhibiting mouse common carotid artery thrombosis and relieving cerebral ischemia reperfusion injury. Experiments finally confirm that benzbromarone can inhibit formation of common carotid artery thrombosis, does not affect the blood coagulation function, is low in cytotoxicity, has the drug effect similar to that of aspirin and clopidogrel which are commonly used at present, and can become an effective and safe therapeutic drug for cerebral arterial thrombosis.

The application includes a description of anti-hemojuvelin antibodies and methods for their use in the treatment of myelofibrosis and / or myelofibrosis-related conditions.

Provided herein are devices, systems, methods, and compositions, including compositions for coupling to a surface of an implantable article, the compositions comprising an anticoagulant comprising a direct factor Xa inhibitor and at least one of (a) an antiplatelet drug, (b) an anticoagulant comprising a direct factor IIa inhibitor, and (c) an anti-inflammatory drug comprising colchicine.

Described herein are methods for producing omniphobic coating compositions. The methods provide an extremely facile and economic synthetic process that can be extended to a wide range of substrates for widespread real-world applicability. The omniphobic coating compositions produced herein possess numerous advantageous properties including, but not limited to, high physical durability, aqueous chemical stability, thermal and UV resistance, prolonged room temperature storage, cytocompatibility and impeccable anti-biofouling properties including anti-platelet adhesion. In one aspect, the omniphobic coating composition is produced by the method comprising (a) functionalizing a surface of the article with a plurality of nucleophilic groups to produce a pre-functionalized surface, and (b) contacting the pre-functionalized surface with a perfluorolkylsiloxane comprising an electrophilic group, wherein the plurality of nucleophilic groups on the surface of the article react with the electrophilic group on the perfluoroalkylsiloxane to covalently bond the perfluoroalkylsiloxane to the surface of the article.

The present disclosure provides methods for determining whether a subject has platelet hyperreactivity. Further provided are methods for determining risk of developing a platelet-mediated cardiovascular and / or limb event in a subject, as well as determining whether a subject has a condition associated with platelet hyperreactivity. Still further provided are methods for preventing a cardiovascular and / or limb event in a subject in need thereof; treating or preventing a condition associated with platelet hyperreactivity in a subject in need thereof; and, monitoring the progression of a condition associated with platelet hyperreactivity in a subject diagnosed with the condition. Methods for determining the effect of an antiplatelet treatment on development of a condition associated with platelet hyperreactivity in a subject diagnosed with the condition, and identifying an antiplatelet treatment useful for slowing down the progression or treating a condition associated with platelet hyperreactivity in a subject diagnosed with the condition are also provided.

The present disclosure relates to reagents, kits and methods for the detection of anti-PF4 antibodies and the diagnosis of heparin-free thrombotic events, including vaccine-induced thrombocytopenia. The present disclosure provides a method comprising: (i) contacting a whole blood, plasma or serum sample obtained from a subject with an agent comprising: (a) a binding molecule selected from the group consisting of platelet factor 4 protein (PF4), a PF4 fragment capable of binding to an anti-PF4 antibody, and an anti-idiotype antibody of an antiplatelet factor 4 antibody (anti-PF4 antibody); and (b) a solid support wherein the binding molecule (a) is covalently bound to the surface of the solid support (b) and wherein the binding molecule (a) does not comprise heparin or a heparin substitute, and (ii) analysing the sample to detect a complex formed by the reagent and the anti-PF4 antibody wherein detecting the complex indicates that the sample contains the anti-PF4 antibody.

The invention provides an isoquinoline derivative with a novel structure, a pharmaceutically acceptable salt thereof, a preparation method of the isoquinoline derivative, a pharmaceutical composition containing the isoquinoline derivative and pharmaceutical application of the isoquinoline derivative, and belongs to the technical field of medicines. In-vitro experiments show that the isoquinoline derivative has significant inhibitory activity on arachidonic acid-induced platelet aggregation, and the antiplatelet activity of part of compounds is superior to that of aspirin. In a rat carotid artery thrombosis model induced by FeCl3, the isoquinoline derivative remarkably prolongs thrombosis time and reduces thrombus weight, and the in-vivo antithrombotic curative effect of the isoquinoline derivative is equivalent to that of aspirin and ticagrelor. A mouse tail bleeding model shows that the side effects of bleeding amount and bleeding time of the isoquinoline derivative are obviously lower than those of aspirin and ticagrelor. Therefore, the series of isoquinoline derivatives have the advantages of efficient antithrombotic effect and low bleeding risk, and have good application prospects in preparation of drugs for preventing and treating thrombotic diseases. In addition, the preparation method provided by the invention has the advantages of easily available raw materials, simple steps and strong operability, and the obtained target product has high quality and good efficiency.

The embodiments herein provide hemostatic compositions, methods, and kits comprising composite polymer particles. Upon contact with blood or other physiological fluids, the composite particles adsorb fluid and aggregate into a shape-retentive mass that halts bleeding. In certain embodiments, the particles comprise polymers of 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, or combinations thereof. The particles may be used alone or blended with additional hemostatic agents. Methods of inducing hemostasis are provided for diffuse oozing, or surgical, mucosal, organ surface, fragile tissue or traumatic bleeding, including in patients receiving anticoagulant or antiplatelet therapy. Kits comprising sterile packages of composite particles, optionally with applicators, substrates, or sprays, are disclosed. The compositions exhibit intrinsic hemostatic activity and synergistically enhance the performance of conventional hemostats, achieving rapid clotting. After hemostasis is achieved, the compositions remain in situ as a conforming protective layer, reducing the need for additional covering materials and decreasing risk of re-bleeding.

The application discloses a method for improving blood compatibility of PMP hollow fiber membranes for ECMO by using zwitterionic-nano silver antifouling and antibacterial coating, and the steps of the preparation method are as follows: (1) dissolving zwitterionic polymers and dopamine hydrochloride with different concentrations in PBS; (2) after cleaning the PMP membrane, the PMP membrane is soaked in the modified liquid obtained in step (1), so that the zwitterionic polymers are adhered to the membrane; (3) the above PMP hollow fiber membrane is sequentially immersed in AgNO3 solution, deionized water and NaBH4 solution, so that Ag + is fixed on the membrane surface, and silver nanoparticles are formed in situ on the membrane surface. Experiments prove that the method for improving blood compatibility of PMP hollow fiber membranes for ECMO by using zwitterionic-nano silver coating is simple and has strong universality, and the prepared PMP hollow fiber membrane has high hydrophilicity, excellent anti-platelet adsorption, anti-platelet adsorption and anti-protein adhesion performance, is beneficial to inhibiting thrombosis, and has good blood compatibility and biocompatibility.

Disclosed is a method for evaluation of residual platelet thrombotic potential in a patientundergoing antiplatelet therapy with acetylsalicylic acid which comprises determination ofplatelet tissue factor (TF) expression in a patient's blood sample.

Disclosed in the present invention is the use of an extracellular vesicle as a marker for immune thrombocytopenia. The extracellular vesicle (EV) is derived from platelets, and the extracellular vesicle is secreted by an anti-platelet membrane glycoprotein autoantibody by means of activating the AKT pathway. On the basis of the use, provided is a detection kit for diagnosing immune thrombocytopenia, wherein the detection kit can be used for detecting extracellular vesicles.

The present application provides a kind of nereid polypeptide antithrombotic preparation, belong to the technical field of biopharmaceuticals.The present application finds that nereid plasmin polypeptide can inhibit the reaction of thrombin and fibrinogen to generate fibrin, thereby inhibiting the blood clotting reaction through in vitro test.Nereid plasmin polypeptide is determined for in vitro anti-platelet aggregation activity, and the inhibition rate of 640 μg / ml nereid plasmin polypeptide for anti-platelet aggregation is 75.68%, close to the inhibition effect of 1 mg / ml aspirin.The present application finds that nereid plasmin polypeptide group has the pharmacodynamic effect of reducing the weight of thrombus and the ratio of thrombus weight and length through nereid plasmin polypeptide antithrombotic effect test, has good antithrombotic effect, and can be used as nereid polypeptide antithrombotic preparation.